The human papilloma viruses (HPVs) are among the widespread sexually transmitted pathogens infecting women. Like HIV, HPV’s importance resides in the potential long-term consequences of infection with selective types. HPV types 16 and 18 are deemed to be carcinogens and/or co-carcinogens for the female genital tract. HPV DNA has been found in all grades of cervical intraepithelial neoplasia (CIN) as well as in invasive cervical cancer. Types 16 and 18 are present in approximately 70% of cancers. Types 10, 11, 31, 33, 35, 46, 51, and 56 account for most of the remaining cancers for which DNA typing has been done.
Using the HPV major coat protein, L1, researchers have developed 2 HPV vaccines: a quadrivalent vaccine with HPV 6/11/16/18 and a bivalent vaccine with HPV 16/18. The antibodies induced by the vaccines persist for at least 5 years.1 The presumed protection from these vaccines does not lessen the importance of continued cytological monitoring of the cervix and vagina.
Beller and Abu-Rustum2 reported 2 cases of cervical cancer after HPV vaccination. One case involved a poorly differentiated adenocarcinoma for which HPV has not been implicated as a cause despite a high prevalence of HPV DNA. The second case was in a young vaccinated female with cervical cancer associated with HPV 31, a type not covered by the current vaccines. The value of Beller and Abu-Rustum’s report is not primarily in the data but rather in what the data infer: that lifelong screening by periodic cytological cervical smears for cervical cancer is not negated by prior vaccination.
As demonstrated in the second case, a number of HPV types not included in the vaccines have been linked to cervical precancerous and cancerous lesions. In some countries, types 16 and 18 are not the most endemic HPV types associated with cervical cancer. Over time, the elimination of HPV 16 and 18 will probably result in a shift in the prevalence of HPV types. Other oncogenic types will probably predominate as causes of precancerous and cancerous lesions.
A final concern, not expressed in the article by Beller and Abu-Rustum,2 centers on the duration of induced immunity. Compared with live vaccines, subparticle vaccines have a limited period of effectiveness.
The advent of the prophylactic effectiveness of the HPV vaccines in reducing CIN and preinvasive genital lesions is a wonderful achievement, but it does not lessen the need for lifelong cytological screening after vaccination.
|
FROM PHYSICIANS PRACTICE
Tax Schemes Every Physician Should Avoid Ike Devji, JD, January 31, 2012 The next 60 days marks the final push to sell physicians across the United States tax plans of both good and questionable value. Boosting Collections at Your Medical Practice: Whose Job Is It? P.J. Cloud-Moulds, January 28, 2012 Embrace the relationship between your billing company and your medical practice staff. Managing Difficult Medical Practice Employees Shelly K. Schwartz, January 27, 2012 Tips for transforming immature staff members into great employees. Prevent Physician Distraction When Using mHealth Technology Aubrey Westgate, January 25, 2012 As more and more physicians use handheld mobile technology in their day-to-day work, some critics are raising concerns about “distracted doctoring.” Can That Applicant Do the Job at Your Medical Practice?
Karen Zupko, January 25, 2012 If like many communities, yours has significant numbers of non-English speaking people with whom neither you nor your staff are able to converse, your practice is at a serious disadvantage.
MOST POPULAR
|
|
CancerNetwork |
CME LLC |
ConsultantLive |
Diagnostic Imaging |
Musculoskeletal Network |
OBGYN.net |
PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources
© 1996 - 2012 UBM Medica LLC, a
UBM company
Privacy Statement -
Terms of Service -
Advertising Information -
Editorial Policy Statement -
UBM Medica Network Privacy Policy